RCEL | tickerfilter.com

Fundamental analysis

25%

Profitability 25%

Dept financing 9%

Liquidity 75%

Performance 17%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

9.87%

1 Month

0.16%

3 Months

22.02%

6 Months

62.39%

1 Year

-5.49%

2 Year

90.98%

Key data

Stock price

$13.10

P/E Ratio

-4.88

DAY RANGE

$12.88 - $13.53

EPS

-$1.95

52 WEEK RANGE

$7.95 - $18.93

52 WEEK CHANGE

-$9.53

MARKET CAP

243.264 M

YIELD

N/A

SHARES OUTSTANDING

25.990 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

11/07/2024

BETA

1.86

PUBLIC FLOAT

AVERAGE 10 VOLUME

$122,119

AVERAGE 30 VOLUME

$98,091

Company detail

CEO: James M. Corbett
Region: US
Website: avitamedical.com
Employees: 130
IPO year: -

Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

AVITA Medical Inc. operates as a commercial-stage regenerative tissue company in the United States, Australia, and the United Kingdom. Its lead product is RECELL System, a device that enables healthcare professionals to produce a suspension of Spray-On Skin cells using a small sample of the patient's own skin for use in the treatment of acute thermal burns in patients eighteen years and older. The company was incorporated in 2000 and is based in Valencia, California.

RCEL - AVITA Medical, Inc.